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NKX3.1 binding to GPX2, QSCN6, SOD1, and SOD2 promoters contributes to
antioxidant response regulation via transactivation
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Abstract: NKX3.1 is a prostate-specific transcription factor that is regulated by the androgen receptor in the presence of androgens.
It functions as a tumor suppressor against the development of prostatic intraepithelial neoplasia and primary prostate tumors. Here, a
recognized approach combining in silico analysis and chromatin immunoprecipitation (ChIP) was used to identify the genes directly
regulated by NKX3.1 promoter binding in LNCaP cells. Quantitative PCR using ChIP-captured DNAs as templates verified a subset of
NKX3.1 binding motifs. Thus, in the presence of androgens, significant NKX3.1 binding occurs to promoters of GPX2, QSCN6, SOD1,
and SOD2 genes that contribute to oxidative stress regulation. Our data demonstrate that NKX3.1 is found in a DNA-bound state
transiently at a basal level even in the absence of androgens; an increase in androgens promotes NKX3.1 binding, perhaps temporally
rather than spatially, to the specific sites. The overall changes potentiate the transcriptional regulatory activity of NKX3.1, although
they are dependent on the androgen receptor for the target promoters. The results suggest that NKX3.1 contributes to an antioxidant
response by regulating the transcription of oxidative stress regulators by direct promoter binding.
Key words: Chromatin immunoprecipitation, promoter binding, androgen, NKX3.1, MatInspector

1. Introduction
Prostate cancer is the most common malignancy among
males in developing countries and constitutes 29% of
all cancer cases among males in the United States (Weir
et al., 2003; Siegel et al., 2013). While surgical treatment
of organ-confined disease may be curative, prostate
cancer that has progressed to the hormone-independent
stage is nearly always fatal. Although the outcome is
nearly inevitable once conventional hormone ablation
therapy has been initiated, it is important to understand
the spectrum of genes regulated in hormone-sensitive
disease and recognize whether any of these are active
in hormone refractory tumors of the prostate. One of
the androgen receptor (AR)-regulated genes (Nelson
et al., 2002; Sato et al., 2003; Masuda, 2005; Beier et al.,
2009) is NKX3.1, and it encodes a homeobox-containing
protein with an important function in normal prostate
development during embryogenesis under the regulation
of androgens. It also acts as a tumor suppressor in prostate
cancer (Korkmaz et al., 2000a; Abate-Shen et al., 2008).
As described independently by 2 groups, it functions in
the DNA damage repair response by activating ataxia
telangiectasia mutated (ATM) kinase (Bowen et al., 2013;
* Correspondence: bilge.debelec@ege.edu.tr
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Erbaykent-Tepedelen et al., 2014), and compromises the
oxidative damage-mediated response in prostate cancer
cells. Loss of NKX3.1 expression is frequently observed in
prostatic intraepithelial neoplasia and advanced prostate
tumors. However, its expression is restored in castrationresistant prostate tumors. Additionally, the decreased
proliferation in cell culture and alleviated tumorigenesis
in xenografts supports the suppressor role of NKX3.1 (Lei
et al., 2006; Abate-Shen et al., 2008).
Furthermore, the DNA-binding motif of NKX3.1 was
determined as TAAGT(N) using an in vitro protein–DNA
binding assay in a previous study (Steadman et al., 2000).
As a transcription factor, NKX3.1 functions by activating or
repressing the expression of target genes transcriptionally
via its homeo- or TN-domains. Expression of smooth
muscle gamma actin is activated by NKX3.1 along with a
synergistic interaction to serum response factor (Carson
et al., 2000), whereas human ether-a-go-go-related gene
(HERG) promoter activity is repressed through one
functional NKX3.1 binding site on the HERG promoter
(Bowen et al., 2007). As NKX3.1 also represses vascular
endothelial growth factor (VEGF) transcription via its
specific binding site on the VEGF promoter (Zhang et
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al., 2008), NKX3.1 binding on the 2 specific sites on the
PCAN1 promoter was also reported (Abate-Shen et al.,
2008).
In a study involving NKX3.1-deficient mice, NKX3.1
function was compared by microarray, and 29 positively
and 28 negatively (57 potential) regulated targets in
hemizygous (monoallelic) and nullizygous (0 alleles)
mutants were determined in comparison to the wild
type (2 alleles) (Magee et al., 2003). Another microarray
study in NKX3.1-deficient mice showed that 299 genes
and 339 genes were up- and downregulated in 638 target
candidates, respectively. Furthermore, in that study,
glutathione peroxidase 2 (Gpx2), glutathione peroxidase 3
(Gpx3), peroxiredoxin 6 (Prdx6), and sulfhydryl oxidase
Q6 (Qscn6), which are oxidative stress regulators, were
altered in expression by the loss of NKX3.1 (Ouyang et al.,
2005).
This information is important not only for proper
understanding of the role of androgen-regulated NKX3.1
expression in prostate cancer but also for describing its
role in the development and maintenance of the prostate
gland under stress conditions, such as oxidative damage
or inflammation (Mora et al., 1996; Coffey et al., 2002).
Loss or alteration of NKX3.1-dependent regulation of
these interactions might be crucial for understanding the
progression of prostate cancer. In physiological samples,
NKX3.1 binding sites may deviate considerably from the
putative consensus sequences (Nelson et al., 2002; Beier
et al., 2009). It is unclear how specificity of transcription
factors such as AR and NKX3.1 to the response element
is achieved. As NKX3.1 binding to these promoter and
enhancer sequences facilitates interactions with the
repressor transcriptional machinery (Groucho), leading
to gene transcription or repression, finding the sole
targets of the NKX3.1-regulated promoters is essential for
understanding the biology of prostate cancer (Schule et al.,
1988; Truss and Beato, 1993; Suzuki et al., 2003).
In order to define the genes driven by the NKX3.1
transcriptional complex in vivo, we used the combination
of in silico analysis of the NKX3.1 binding motif on
promoter sequences with chromatin immunoprecipitation
(ChIP) as a means to identify genes captured by ChIP for
recognition of endogenous transcription factor assemblies
on gene promoters in vivo (Hecht et al., 1999; Adamson et
al., 2003; Hayakawa et al., 2004; Li et al., 2005; Masuda et
al., 2005; Sun et al., 2006). Finally, binding rates of NKX3.1
on the native promoters of ACTG2, PCAN1, HERG,
GPX2, GSCN6, SOD1, and SOD2 were validated using
quantitative PCR (Q-PCR), and the androgen effect was
also investigated in LNCaP cells.

2. Materials and methods
2.1. Cell culture, serum starvation, and R1881 induction
An LNCaP cell line was obtained from the American
Type Culture Collection (Rockville, MD, USA). The cells
were cultured at 37 °C in RPMI 1640 with 10% FBS in a
humidified atmosphere of 5% CO2. The day after cells split,
the medium was changed to 2% CT-FBS and incubated for
48 h. The medium was then changed to 0.5% CT-FBS and
incubated for an additional 24 h, and synthetic androgen
R1881 (10–8 M) was added for up to 24 h.
2.2. Analysis of NKX3.1 binding motif on the promoters
Promoter sequences (from –9999 to +1; +1 indicates transcription start site) of the target gene candidates were
extracted in FASTA format from the databases (UCSC
Genome Browser and Eukaryotic Promoter Database).
Promoter sequences were then analyzed to extract the
specific NKX3.1 binding motif [TAAGT(N)] by using the
MatInspector tool (www.genomatix.de). Analysis parameters were adjusted to: library, “transcription factor binding sites”, and core similarity, “1”. Finally, specific binding
sites were indicated on the schematic promoter maps of
each gene.
2.3. Antibodies
The anti-NKX3.1 antibody was a gift from Dr Saatçioğlu,
Oslo Biotechnology Center, Norway, and nonspecific
rabbit IgG (Santa Cruz) and HRP-antirabbit secondary
antibody (Amersham) were purchased and used according
to the manufacturer’s recommendations.
2.4. Chromatin immunoprecipitation
LNCaP cells (108) were cultured in 15-cm cell culture
dishes and treated with 10–8 M R1881 for 24 h. Cells
were then fixed by adding 1% formaldehyde to cells for
10 min at room temperature, and then 2.5 M glycine at
1/20 volume was added for 5 min with gentle shaking.
Media were discarded, and cells were washed with PBS
and pelleted. Cell pellets were washed with lysis buffer [10
mM Tris-Cl (pH 7.5), 10 mM NaCl, 3 mM MgCl2, 0.5%
Igepal, 1 mM PMSF, 1X Roche protease inhibitor cocktail]
3 times and centrifuged at 500 × g for 5 min. The pellet
was resuspended in 1 mL of pre-IP dilution buffer [10 mM
Tris-Cl (pH 7.5), 10 mM NaCl, 3 mM MgCl2, 1 mM CaCl2,
4% Igepal, 1 mM PMSF, 1X Roche protease inhibitor
cocktail], and 1% SDS and 200 mM NaCl were added.
Cells were sonicated 3 times for 10 s with 45% power and
50% pulse. Centrifugation was performed at 13,000 × g for
10 min at 4 °C. Supernatant was transferred into a new
tube, and 1 mg of protein from each sample was subjected
to preclearance with 20 µL of protein A/G agarose beads.
Samples were then incubated with 2 µg of anti-NKX3.1
antibody in a rotator at 4 °C overnight. Nonspecific rabbit
IgG was used as a negative control, and 40 µL of protein
A/G agarose beads were added and incubated for an
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additional 3 h. After centrifugation, the supernatant was
removed, and beads were washed with washing buffers
I, II, and III subsequently [wash buffer I: 20 mM Tris-Cl
(pH 8.0), 2 mM EDTA, 1% Triton X-100, 150 mM NaCl,
1 mM PMSF; wash buffer II: 20 mM Tris-Cl (pH 8.0), 2
mM EDTA, 1% Triton X-100, 0.1% SDS, 500 mM NaCl,
1 mM PMSF; wash buffer III: 10 mM Tris-Cl (pH 8.0),
1 mM EDTA, 0.25 M LiCl, 0.5% Igepal, 0.5% sodium
deoxycholate]. Elution of the protein–DNA complexes
was done by incubating the beads with elution buffer [25
mM Tris-Cl (pH 7.5), 10 mM EDTA, 0.5% SDS] at 65 °C
for 30 min. Reverse cross-linking was then performed by
incubation with proteinase-K at 65 °C overnight.
2.5. Q-PCR
To study the amplification of specific NKX3.1 binding sites,
quantitative RT-PCR was performed using a SYBR Green
PCR Kit and the LC480 PCR system (Roche, Germany). The
primers specific for each NKX3.1 binding site on promoters
of the genes are given in the Table. The relative abundance
Table. List of primers used to amplify the target regions covering
NKX3.1 binding motif.
GPX2_1_F ProLC

GCCTCACCAAGTATATTCCATTAG

GPX2_1_R ProLC

CCTCCAGAGACACCTCTTAT

GPX2_2_F ProLC

CAAGTCCTTGTGACTCAGTG

GPX2_2_R ProLC

TTTCCATGGCTGTTCAAGTAT

GPX2_3_F ProLC

TCCACTAAGTTTATCCACCTGT

GPX2_3_R ProLC

TCAGTGCCTCAGCTCTT

QSCN6_F ProLC

GTCCCTGATCTTCGTGTG

QSCN6_R ProLC

CTCTAGGGACGTGGAACT

SOD1_1_F ProLC

ACTACCAAATACAACAGGCA

SOD1_1_R ProLC

AGTGTGAAACAACAATAGAAGC

SOD1_2_F ProLC

ATATTAAGTACTAGGCTGGACG

SOD1_2_R ProLC

CGCCATCATAGCTCACTG

SOD2_F ProLC

GTTGCAAGAAGCAACGGA

SOD2_R ProLC

GTAGCCTAGTAAGCTGTTAAGTAT

HERG_F ProLC

GTGCAGCTCCTATGCAGA

HERG_R ProLC

CAAGACAATCTGAAGGCCC

ACTG2_F ProLC

CACTCTGGGCAGCTTAT

ACTG2_R ProLC

CCAGCTGACGGTGTGTTA

PCAN1_1_F ProLC

CACTGCCTCTATGCACT

PCAN1_1_R ProLC

GGTATAACTGAACATGCTACCA

PCAN1_2_F ProLC

GCTGCCTGATAACTCATAAGTAAT

PCAN1_2_R ProLC

CTTAGCATTGCCAAGCTG

PCAN1_3_F ProLC

TTTAAGCTCACAGCATTCACA

PCAN1_3_R ProLC

AGCAGTTCACTTTTCTGTATCT
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of each amplicon was calculated using a comparative cycle
of threshold (CT) method with rIgG-precipitated DNA
as an invariant control for promoter binding analysis.
The formula is: (target unknown / reference unknown)
/ (target calibrator / reference calibrator), where ‘target
unknown’ is precipitated with NKX3.1 ab from R1881treated cells, ‘target calibrator’ is precipitated with rabbit
IgG from R1881-treated cells, ‘reference unknown’ is
precipitated with NKX3.1 ab from untreated cells, and
‘reference calibrator’ is precipitated with rabbit IgG from
untreated cells. ChIP DNA samples were used as templates.
For Q-PCR analysis on the NKX3.1 mRNA level, mRNA
isolation (RNeasy mRNA Isolation Kit, QIAGEN, the
Netherlands) and cDNA synthesis (Omniscript cDNA
Synthesis Kit, QIAGEN) were performed. The relative
mRNA level was calculated using a comparative CT
method, using GAPDH as an invariant control. Primers
were NKX3.1_F: TCTATCAGCATCTGACAGGTGAA,
NKX3.1_R:
AGCAGGGTTTGTTATGCATGTAG,
GAPDH_F:
CATTGCCCTCAACGACCACTTT,
GAPDH_R: GGTGGTCCAGGGGTCTTACTCC.
2.6. Cell lysis, protein extraction, and blotting
For protein extraction, cells were grown in 6-cm culture
dishes (Sarstedt, Germany) and washed once with PBS
prior to cell lysis. Cells were collected from culture plates
using a cell scraper and transferred to Eppendorf tubes.
Cells were resuspended in 250 µL of modified RIPA buffer
[10 mM Tris-Cl (pH 8.0), 1% Triton X-100, 0.1% SDS,
0.1% sodium deoxycholate, 1 mM EDTA, 1 mM EGTA,
140 mM NaCl] containing protease and phosphatase
inhibitors. Lysates were sonicated for 20 s (25% power,
0.5 cycles) and centrifuged at 12,000 × g for 10 min, and
cleared supernatants were collected into new tubes. Protein
concentrations were determined using BCA assay (Sigma,
UK). SDS-PAGE and western blots were performed under
standard conditions using 50 µg of protein lysate per lane;
proteins were separated on 10%–12% gel and transferred to
a PVDF membrane (Amersham, UK) using a wet transfer
blotter. The PVDF membrane was blocked with 5% dry
milk in TBS-T (Tris-borate-saline solution containing
0.1% Tween 20). Primary and secondary antibody
incubations were performed using TBS-T containing 0.5%
dry milk or 5% BSA at room temperature for 1 h or at 4 °C
overnight. Membranes were developed using ECL prime
reagent (Amersham) for 5 min and were photographed
using Kodak X-ray film in a dark room.
2.7. Statistics and criteria of significance
The results were obtained from 3 independent experiments. Statistical analyses were performed using Student’s
t-test, and the P-values were calculated by comparing each
treatment to the control.
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3. Results
3.1. MatInspector (in silico) analysis supports the
regulation data
In order to identify the NKX3.1 binding sites on GPX2,
QSCN6, SOD1, and SOD2 promoters, the sequences from
–9999 to +1 (transcription start site) were extracted from
the experimentally verified EPD (Cavin Perier et al., 1998)
and UCSC, and the specific binding motif for NKX3.1 was
analyzed using the MatInspector tool. NKX3.1 binding sites
were then schematically mapped (Figure 1). We found 36
NKX3.1 consensus sites [TAAGT(N)] in 4 promoter regions,
and 7 out of 36 proximal promoters were chosen for validation as potential binding regions. Since we described the list
of genes with promoters containing NKX3.1 sequences and
presumed that altered expression of the promoters previously
reported by Ouyang et al. (2005) might be controlled directly
by NKX3.1 recruitment into transcriptional complexes, further validations in specific binding regions were carried out.
Primers covering particular promoter sequences were designed using LightCycler primer-probe design software. The
PCR validations were then performed using genomic DNA
as a template. Finally, the binding sequences were examined
in silico as regions of interest for ChIP studies.
3.2. Validation of site specificity of NKX3.1 binding
Since LNCaP is a well-known androgen-responsive
prostate cancer cell line, an increase in the expression of
NKX3.1 was shown as an indicator of androgen induction.

RNA was prepared from LNCaP cells, either untreated
or treated with synthetic androgen R1881 (10–8 M), and
transcriptional alteration of androgen-responsive gene
NKX3.1 was induced for up to 24 h; a time-dependent increase in NKX3.1 mRNA level by Q-PCR, in comparison
to GAPDH, was detected, which was the quality control
of expression (Figure 2A). Consistent with transcriptional
increase, after administration of R1881 for 24 h, a clear increase was also observed in protein expression of NKX3.1
(Figure 2B).
In order to analyze the promoters regulated by direct
recruitment of NKX3.1 in vivo, ChIP was performed
using a specific antibody against NKX3.1 in LNCaP
cells. Q-PCR studies were then performed using primers
covering the [TAAGT(N)] consensus sites to validate the
precipitates from ACTG2, HERG, and PCAN1 that are
known targets of NKX3.1, as an experimental control.
Finally, binding ratios of NKX3.1 were measured using
Q-PCR and calculated for each promoter region of interest
by comparing the amplified precipitation of an R1881treated sample to an untreated sample. NKX3.1 antibodyprecipitated samples were normalized to nonspecific
IgG. When known transcriptional targets from previous
studies were verified in LNCaPs, the binding ratios were
given as fold-change of 6.1 for ACTG2, 8.7 for HERG, and
24.6-, 57.3-, and 5.3-fold for PCAN1_1, PCAN1_2, and
PCAN1_3 on the PCAN1 promoter.

Figure 1. MatInspector analysis yielded 36 NKX3.1 putative binding sites in 4 promoter regions. DNA was
analyzed using the criteria of high occurrence of TAAGT(N) sequences on proximal promoters. The regions of
interest in proximal regions are numbered in red as amplicon numbers.
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Fold change of NKX3.1 mRNA

NKX3.1

A

20

GPX2, QSCN6, SOD1, and SOD2 promoters. Therefore,
we suggest that NKX3.1 regulates these genes transcriptionally.

14.9

11.9

15
7.9

10

8.7

5
0

2
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R1881

24

(h)

NKX3.1

GAPDH

Figure 2. NKX3.1 expression is inducible with androgens. A)
NKX3.1 gene expression was induced by R1881 at the mRNA
level at about 15-fold of control at 2, 4, 6, and 24 h; P < 0.001.
B) NKX3.1 expression also increased at the protein level at 24 h.
GAPDH western blot was presented as the loading control. Representative figure was obtained from 3 independent experiments.

Because the expression of genes was altered by NKX3.1
expression, as reported in a previous study (Ouyang et al.,
2005), NKX3.1 binding ratios on the 3 specific motifs of
the GPX2 promoter were also examined, and the regions
GPX2_1, GPX2_2, and GPX2_3 increased 10.3-, 24.2, and 9.6-fold, respectively. In addition, the 3 adjacent
NKX3.1 motifs on the QSCN6 promoter resulted in a 22fold increase in binding. The associations on the 2 binding sites of the SOD1 promoter, SOD1_1 and SOD1_2,
also increased 9.3- and 36.4-fold, respectively; the SOD2
promoter was 24-fold higher (Figure 3) in comparison
to androgen-negative controls. Thus, we observed that
NKX3.1 precipitations resulted in similar representations
of the promoters analyzed where the overall changes were
significantly altered with R1881 treatment in comparison
to untreated control samples.
Taken together, we found that 7 promoter regions significantly bound 4 nonredundant promoters with NKX3.1,
either with or without R1881 (Figure 3). NKX3.1 binding
on the known transcriptional target (ACTG2, HERG, and
PCAN1) promoters was validated by enhanced NKX3.1
expression upon R1881 treatment in LNCaP cells; additionally, NKX3.1 binding was first demonstrated at the
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4. Discussion
Antiandrogen therapy usually results in involution of
both normal prostate glands and prostatic tumors in the
early stages of the disease if the disease is still androgendependent. However, in the case of the latter, recurrence
of the tumor in almost all cases in a few months or years
is described as an androgen-independent state of the prostate disease. Such tumors appear autonomous in that a
variety of AR-target genes are expressed (e.g., NKX3.1)
without the ligand (Korkmaz et al., 2000b; Skotheim et al.,
2003). Since the originated tumor cells are usually errorprone, this may render the development of a clone that
is selected during hormone ablation therapy (Dryhurst
et al., 2012). There is strong evidence that selected clones
represent a loss of oxidative stress regulation as well as
androgen response. Consistent with a recent expression
profiling study showing alterations in several prooxidant
and antioxidant enzyme genes involving Gpx2 and Qscn6
in NKX3.1-mutant mice (Ouyang et al., 2005), our study
demonstrated that NKX3.1 bound to GPX2 and QSCN6
promoters and that the binding increased with androgen
administration. In addition, we used R1881 instead of
5α-dihydrotestosterone (DHT) in our experiments, since
R1881 is a synthetic androgen and is not metabolized as
rapidly as DHT in cell culture (Asselin et al., 1979). Further, it is 10 times more potent than DHT and corresponds
to physiological levels (1–100 nM) covering all ages
(Ripple et al., 1997). Our data imply that transcriptional
changes could also be regulated via NKX3.1 binding directly. Although the SOD1 and SOD2 were not changed in
NKX3.1-mutant mice in a previous report (Ouyang et al.,
2005), we observed significant NKX3.1 binding to SOD1
and SOD2 proximal promoters. This discrepancy suggests that enhanced NKX3.1 binding on SOD1 and SOD2
promoters did not lead to altered expressions of these enzymes due to posttranscriptional regulation of mRNA or
a requirement for an additional coactivator after NKX3.1
binding.
Since transcriptional control has been an attractive
area for drug development research in recent years, identification of the molecular targets of NKX3.1 transcription
factor can lead to new therapeutic strategies for prostate
cancer. Providing insight into a more complete spectrum
of the development of inhibitors for certain targets may
circumvent the function of NKX3.1 and the development
of ligand-independent AR action. The development of inhibitors of key targets in late-stage hormone-independent
disease will greatly increase our basic understanding of the
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Figure 3. Q-PCR verified that 4 genes are regulated by NKX3.1. Binding ratios (antibody-specific amount of precipitated DNA compared to nonspecific IgG) of NKX3.1 were measured using Q-PCR and calculated for each promoter region of interest by comparing
binding ratios. Graphics showed that the relative NKX3.1 binding to proximal promoters increases when androgen is administered
to the cells. The ratio was calculated in comparison to untreated binding; P < 0.01.

role of AR and NKX3.1 and their effects on prostate cells,
as well as providing new therapeutic approaches.
Moreover, in previous studies, researchers developed
and utilized arrays of all intergenic DNA, as in the yeast
genome, to identify promoters bound and activated during
the cell cycle. They also correlated gene expression changes
to a network of coexpressed genes of the steps of the cell
cycle (Hartemink et al., 2001; Bar-Joseph et al., 2003).
These studies were immediately extended to mammalian
cells by analysis of the transcription factor E2F (Ren et
al., 2000) and further extended to an analysis of c-myc
binding (Li et al., 2003). Thus, it is important to appreciate
that the initial approach was one of sampling by use of
portions of promoters and a fraction of the promoters
of the genome. Nevertheless, by careful validation and
functional analysis, numerous E2F and myc-regulated
genes were identified and correlated with tumor
phenotype. Moreover, these studies suggested that more
AR-target genes would be determined, and these genes
could be observed in a physiological context of coordinate

regulation by endogenous levels of AR in living cells. Thus,
while this study is focused on prostate cancer and oxidative
stress regulation via NKX3.1, it can be extrapolated to
other transcriptional factors and/or types of cancers. The
methodology proposed here is not limited to prostate
cell lines and may describe other tissue-specific genes
whose expression might be modulated by androgens via
NKX3.1. Whether they exert any transcriptional changes
in prostate cell lines, this type of data has to be evaluated
in a different setting where expression correlation can be
studied. NKX3.1 binding sites regulating transcription
might vary in the absence and presence of R1881; perhaps
the AR-binding is influenced by recruiting to complexes
at different magnitudes, although a different context of
promoters needs to be studied.
Acknowledgment
This research was funded by the Scientific and Technology
Research Council of Turkey (TÜBİTAK), Project 106S200
to KSK.

645

DEBELEÇ BÜTÜNER and KORKMAZ / Turk J Biol

References
Abate-Shen C, Shen MM, Gelmann E (2008). Integrating
differentiation and cancer: the Nkx3.1 homeobox gene in
prostate organogenesis and carcinogenesis. Differentiation 76:
717–727.

Hecht A, Litterst CM, Huber O, Kemler R (1999). Functional
characterization of multiple transactivating elements in betacatenin, some of which interact with the TATA-binding protein
in vitro. J Biol Chem 274: 18017–18025.

Adamson E, de Belle I, Mittal S, Wang Y, Hayakawa J, Korkmaz K,
O’Hagan D, McClelland M, Mercola D (2003). Egr1 signaling
in prostate cancer. Cancer Biol Ther 2: 617–622.

Korkmaz KS, Korkmaz CG, Ragnhildstveit E, Kizildag S, Pretlow
TG, Saatcioglu F (2000a). Full-length cDNA sequence and
genomic organization of human NKX3A—alternative forms
and regulation by both androgens and estrogens. Gene 260:
25–36.

Asselin J, Melancon R, Gourdea Y, Labrie F, Bonne C, Raynaud JP
(1979). Specific binding of [3H]-methyltrienolone to both
progestin and androgen binding components in human benign
prostatic hypertrophy (BPH). J Steroid Biochem 10: 483–486.
Bar-Joseph Z, Gerber GK, Lee TI, Rinaldi NJ, Yoo JY, Robert F,
Gordon DB, Fraenkel E, Jaakkola TS, Young RA et al. (2003).
Computational discovery of gene modules and regulatory
networks. Nat Biotechnol 21: 1337–1342.
Beier CP, Schmid C, Gorlia T, Kleinletzenberger C, Beier D, Grauer
O, Steinbrecher A, Hirschmann B, Brawanski A, Dietmaier C
et al. (2009). RNOP-09: pegylated liposomal doxorubicine and
prolonged temozolomide in addition to radiotherapy in newly
diagnosed glioblastoma—a phase II study. BMC Cancer 9: 308.
Bowen C, Ju JH, Lee JH, Paull TT, Gelmann EP (2013). Functional
activation of ATM by the prostate cancer suppressor NKX3.1.
Cell Rep 4: 516–529.
Bowen C, Stuart A, Ju JH, Tuan J, Blonder J, Conrads TP, Veenstra
TD, Gelmann EP (2007). NKX3.1 homeodomain protein binds
to topoisomerase I and enhances its activity. Cancer Res 67:
455–464.
Carson JA, Fillmore RA, Schwartz RJ, Zimmer WE (2000). The
smooth muscle gamma-actin gene promoter is a molecular
target for the mouse bagpipe homologue, mNkx3-1, and serum
response factor. J Biol Chem 275: 39061–39072.
Cavin Perier R, Junier T, Bucher P (1998). The Eukaryotic Promoter
Database EPD. Nucleic Acids Res 26: 353–357.
Coffey RN, Watson RW, O’Neill AJ, McEleny K, Fitzpatrick JM
(2002). Androgen-mediated resistance to apoptosis. Prostate
53: 300–309.
Dryhurst D, McMullen B, Fazli L, Rennie PS, Ausio J (2012). Histone
H2A.Z prepares the prostate specific antigen (PSA) gene for
androgen receptor-mediated transcription and is upregulated
in a model of prostate cancer progression. Cancer Lett 315:
38–47.

Korkmaz KS, Korkmaz CG, Ragnhildstveit E, Pretlow TG, Saatcioglu
F (2000b). An efficient procedure for cloning hormoneresponsive genes from a specific tissue. DNA Cell Biol 19:
499–506.
Lei Q, Jiao J, Xin L, Chang CJ, Wang S, Gao J, Gleave ME, Witte
ON, Liu X, Wu H (2006). NKX3.1 stabilizes p53, inhibits AKT
activation, and blocks prostate cancer initiation caused by
PTEN loss. Cancer Cell 9: 367–378.
Li W, Meyer CA, Liu XS (2005). A hidden Markov model for
analyzing ChIP-chip experiments on genome tiling arrays and
its application to p53 binding sequences. Bioinformatics 21:
i274–282.
Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B (2003).
A global transcriptional regulatory role for c-Myc in Burkitt’s
lymphoma cells. Proc Natl Acad Sci U S A 100: 8164–8169.
Magee JA, Abdulkadir SA, Milbrandt J (2003). Haploinsufficiency at
the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive
gene regulation during tumor initiation. Cancer Cell 3: 273–
283.
Masuda K, Werner T, Maheshwari S, Frisch M, Oh S, Petrovics G,
May K, Srikantan V, Srivastava S, Dobi A (2005). Androgen
receptor binding sites identified by a GREF_GATA model. J
Mol Biol 353: 763–771.
Mora GR, Prins GS, Mahesh VB (1996). Autoregulation of androgen
receptor protein and messenger RNA in rat ventral prostate is
protein synthesis dependent. J Steroid Biochem Mol Biol 58:
539–549.
Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J,
Hood L, Lin B (2002). The program of androgen-responsive
genes in neoplastic prostate epithelium. Proc Natl Acad Sci U
S A 99: 11890–11895.

Erbaykent-Tepedelen B, Karamil S, Gonen-Korkmaz C, Korkmaz KS
(2014). DNA damage response (DDR) via NKX3.1 expression
in prostate cells. J Steroid Biochem Mol Biol 141: 26–36.

Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C (2005). Lossof-function of Nkx3.1 promotes increased oxidative damage in
prostate carcinogenesis. Cancer Res 65: 6773–6779.

Hartemink AJ, Gifford DK, Jaakkola TS, Young RA (2001). Using
graphical models and genomic expression data to statistically
validate models of genetic regulatory networks. Pac Symp
Biocomput: 422–33.

Ren B, Robert F, Wyrick JJ, Aparicio O, Jennings EG, Simon I,
Zeitlinger J, Schreiber J, Hannett N, Kanin E et al. (2000).
Genome-wide location and function of DNA binding proteins.
Science 290: 2306–2309.

Hayakawa J, Mittal S, Wang Y, Korkmaz KS, Adamson E, English C,
Ohmichi M, McClelland M, Mercola D (2004). Identification
of promoters bound by c-Jun/ATF2 during rapid large-scale
gene activation following genotoxic stress. Mol Cell 16: 521–
535.

646

Ripple MO, Henry WF, Rago RP, Wilding G (1997). Prooxidantantioxidant shift induced by androgen treatment of human
prostate carcinoma cells. J Natl Cancer Inst 89: 40–48.

DEBELEÇ BÜTÜNER and KORKMAZ / Turk J Biol
Sato K, Tsuchiya N, Habuchi T, Satoh S, Shimoda N, Kato T (2003).
Total cystoprostatectomy in the treatment of locally advanced
prostate carcinoma. Aktuelle Urol 34: 259–261.

Suzuki H, Ueda T, Ichikawa T, Ito H (2003). Androgen receptor
involvement in the progression of prostate cancer. Endocr
Relat Cancer 10: 209–216.

Schule R, Muller M, Kaltschmidt C, Renkawitz R (1988). Many
transcription factors interact synergistically with steroid
receptors. Science 242: 1418–1420.

Truss M, Beato M (1993). Steroid hormone receptors: interaction
with deoxyribonucleic acid and transcription factors. Endocr
Rev 14: 459–479.

Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA
Cancer J Clin 63: 11–30.

Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal
A, Ward E, Anderson RN, Edwards BK (2003). Annual report
to the nation on the status of cancer, 1975-2000, featuring the
uses of surveillance data for cancer prevention and control. J
Natl Cancer Inst 95: 1276–1299.

Skotheim RI, Korkmaz KS, Klokk TI, Abeler VM, Korkmaz CG,
Nesland JM, Fossa SD, Lothe RA, Saatcioglu F (2003). NKX3.1
expression is lost in testicular germ cell tumors. Am J Pathol
163: 2149–2154.
Steadman DJ, Giuffrida D, Gelmann EP (2000). DNA-binding
sequence of the human prostate-specific homeodomain
protein NKX3.1. Nucleic Acids Res 28: 2389–2395.

Zhang H, Muders MH, Li J, Rinaldo F, Tindall DJ, Datta K (2008).
Loss of NKX3.1 favors vascular endothelial growth factor-C
expression in prostate cancer. Cancer Res 68: 8770–8778.

Sun H, Palaniswamy SK, Pohar TT, Jin VX, Huang TH, Davuluri RV
(2006). MPromDb: an integrated resource for annotation and
visualization of mammalian gene promoters and ChIP-chip
experimental data. Nucleic Acids Res 34: D98–103.

647

